Sanofi, Lexicon Draw Complete Response Letter for Diabetes Treatment

Drug Industry Daily
A A
The FDA has pushed the pause button on Sanofi’s and Lexicon’s diabetes treatment Zynquista (sotagliflozin) two months after an advisory committee panel deadlocked over the drug’s safety profile.

To View This Article:

Login

Subscribe To Drug Industry Daily